

16th November, 2019

To, The Listing Department, **BSE Limited** P.J. Towers, Dalal Street, Fort Mumbai – 400 001

Scrip Code: 504351 Scrip Id: EMPOWER

Dear Sir/ Madam,

Subject: Newspaper Clipping of Outcome of Board Meeting held on 14th November, 2019.

Pursuant to regulation 33 of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors at their meeting held on 14th November, 2019 have inter-alia considered, approved the unaudited financial results for the quarter and half year ended 30th September, 2019.

In continuation to the same, the newspaper clipping duly published in English Newspaper (All Edition) and Marathi Newspaper (Mumbai Edition) dated 16th November, 2019 is enclosed herewith.

This is for your information and records.

Thanking You,

For Empower India Limited

Authorised Signatory

Empower India Limited CIN: L51900MH1981PLC023931 Reg. Office: 25 / 25A, II Floor, 327, Nawab Building, D.N.Road, Fort, Mumbai – 400 001. Phone:022- 22045055, 22045044, Mobile/Helpdesk No.:9702003139 Email:info@empowerindia.in; Website: www.empowerindia.in

WWW.FINANCIALEXPRESS.COM

FINANCIAL EXPRESS

EMPOWER INDIA LIMITED

CIN: L51900MH1981PLC023931

Regd Office: 25 /25A, Ilnd Floor, 327, Nawab Building, D.N.Road, Fort, Mumbai - 400 001 Phone: 022- 22045055, 22045044, Mobile/Helpdesk No.: 9702003139 Email: info@empowerindia.in; Website: www.empowerindia.in

Extracts of the Statement of Un-audited Financial Results for the Quarter and Half Year Ended 30" September, 2019. (Rs in Lakhe

Particulars	A STAR STAR	Standalone			Consolidated		
Particulars		Six months ended 30.09.2019 (Unaudited)	ended 30.09.2018	Quarter ended 30.09.2019	Six months ended 30.09.2019 (Unaudited)	a final sector and a sector	
Total income from operations (net) Net Profit/(Loss)for a period	(516.00)	,0.00	568.67	(516.00)	0.00	568.67	
(before tax and exceptional items) Net Profit/(Loss)for a period before tax	(20.79)	(15.64)	17.13	(20.79)	(15.64)	17.13	
(after exceptional items)	(1455.85)	(1450.70)	17.13	(1455.85)	(1450.70)	17.13	
Net Profit / (Loss) for the period after tax	(1455.85)	(1450.70)	17.13	(1455.85)	(1450.70)	17.13	
Total Comprehensive Income for the period	(1455.85)	(1450.70)	17.13	(1455.85)	(1450.70)	17.13	
Paid -up Equity Share Capital (Share of Re. 1/- each) Earning per equity share	11637.99	11637.99	11637.99	11637.99	11637.99	11637.99	
Basic:	(0.13)	(0.12)	0.0015	(0.13)	(0.12)	0.0015	
Diluted:	(0.13)	(0.12)	0.0015	(0.13)	(0.12)	0.0015	

The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of Unaudited Financial Result for the quarter and half year ended is available on the website of the Stock Exchange (www.bseindia.com). Figures of the previous year have been re-grouped/ re-arranged / re-classified wherever considered necessary. For Empower India Limited

Place: Mumbai Date: 14th November, 2019

Sd/-Rajgopalan Iyengar Director DIN: 00016496

CONSOLIDATED FINVEST & HOLDINGS LIMITED Regd. Off. : 19" K.M., Hapur-Bulandshahr Road, P.O. Gulaothi, Dist Bulandshahr (U.P.) - 203408

Head Office : Plot No. 12, Sector B-1, Local Shopping Complex, Vasant Kunj, New Delhi- 110070 Tel. No.: 011-26139258, 011-40322100, CIN: L33200UP1993PLC015474 E-mail: cs_cfhl@jindalgroup.com, Website: www.consofinvest.com

EXTRACTS OF THE STANDALONE AND CONSOLIDATED UN-AUDITED FINANCIAL RESULTS THE OHADTED AN

PARTICULARS	Quarter Ended 30 th September 2019	2018	Half Year ended 30 th September 2019	Quarter Ended 30 th September 2019	Quarter Ended 30 th September 2018	Half Year ended 30 th September 2019
7.111		Standalone	Standalone	Consolidated	Consolidated	Consolidated
Total Income from operations	41	99	337	353	387	1,028
Net Profit for the period (before Exceptional items, Share of Profit of associates and tax)	(136)	81	227	338	371	998
Share of Profit/(Loss) of Associates	N.A.	N.A.	N.A.	3,911	(584)	6;420
Net Profit /(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(136)	-35	227	4,249	(259)	7,418
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordiniary Items)	(103)	14	227	4,200	(330)	7,282
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax))	(103)	14	227	4,200	(330)	7,282
Total Comprehensive Income for the period attributable to ownder of the parent	(103)	14.	227	4165	(341)	7225
Paid up Equity Share Capital (Face Value of Rs 10/- each)	3233	3,233	3,233	3,233	3,233	3,233
Earnings Per Share (EPS) (of Rs. 10/- each) on Net Profit (Not annualised) Basic and Diluted	(0.32)	0.04	0.70	12.88	(1.05)	22.35

Financial Results has been prepared in accordance with The Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act 2013 read with the relevant rules issued thereunder.

The Standalone and Consolidated results were reviewed by the Audit Committee and taken on record at the meeting of the Board of Directors at their respective meetings held on 14th November 2019 and limited review of these results has been carried out by the Statutory Auditors of the Company

Nature of Adjustments	Quarter ended 30.09.2019 Standalone	Half year ended 30.09.2019 Standalone
Net Profit/ (Loss) after Tax as per Previous Indian GAAP	(53)	(2)

SATURDAY, NOVEMBER 16, 2019

972

A SOLUTIONS PRIVATE LIMITED

nlink Pharma Investments Private Limited) IN: U74110MH2016PTC280765 Plot No. 5, Sector 19, Sanpada, Navi Mumbal, 400705, Maharashtra, India. anlinkinfo@gmail.com www.genlinkpharma.com CIN: U74110 MH 2016 PTC 280765 ncial Results for the half year ended September 30, 2019

The second	Half Year Ended Sept 30, 2019		
	(Unaudited)	(Unaudited)	(Unaudited)
	19.80	30.00	78.7
dinary items).	2.97	26.98	61.1
nary items)	2.97	26.90	61.1
	2.19	19.90	48.9
riod (after	2.19	19.90	48.9
	, 1.00	1.00	1.0
	23.47	(7.72)	21.2
	0.00	(6.72)	0.0
	2,500.00	2,500.00	2,500.0
	and the second	and the second second	Contractor Autorio
	and the second		angenera an te
)			
S. E	21.93	199.02	489.7
an mile	21.93	199.02	489.7
100	-	·	
Care and the second			
201	1998 - 1998 - 1994 - 1998 -		
Sector same	Canada terra de	and the decision	

eninkpharma.com) neeting held on 14th November, 2019. n 52 (4) of the SEBI (Listing and Other Dit ngany's website (www.geniinkpharma.co Research Limited (erstwhile SMERA Rati

ipany. itember 27, 2021

For Genlink Pharma So	olutions Private Limite
Sd/-	Sd/-
Susheel Koul	Anand Shah
Managing Director	Director
DIN: 00925887	DIN: 00597145

Mumbai - 400 053 www.tvvision.in

3IX MONTH ENDED SEPTEMBER 30, 2019 Re in Lakhe (Evcent EDS)

CONSOLIDATED					
Quarter Ended For Six Month Ended Year Ended					
19 ted)	30-Sep-18 (Un-Audited)	30-Sep-19 (Un-Audited)	30-Sep-18 (Un-Audited)	31-Mar-19 (Audited)	
.54	2,785.24	6,040.72	5,904.17	11,727.15	
65)	(917.28)	(1,386.75)	(1,638.58)	(3,509.13)	
65)	(917.28)	(1,386.75)	(1,638.58)	(3,509.13)	
65)	(917.28)	(1,386.75)	(1,638.58)	(3,509.13)	
	(394.18)	avenas	(784.59)	(1540.67)	
.06)	(1,327.01)	(1,391.57)	(2,454.27)	(5,059.44)	
.00,	(1,021.01)	(1,001.07)	(2,707.27)	(0,00011)	
.45	3,494.45	3,494.45	3,494.45	3,494.45	
-	the second	1,078.83	2,917.91	312.73	
.25)	(2.62)	(3.97)	(4.69)	(10.04)	
25)	(2.62)	(3.97)	(4.69)	(10.04)	

Stock Exchanges under Regulation 33 of the SEBI esults and this extract were reviewed by the Audit e Standalone & Consolidated Quarterly Financial BSE Ltd. (www.bseindia.com) and National Stock

ons, 2015 has been carried out by the auditors on

da

PH

